GRANDE, VERA
 Distribuzione geografica
Continente #
EU - Europa 3.001
NA - Nord America 2.356
AS - Asia 1.748
Continente sconosciuto - Info sul continente non disponibili 326
SA - Sud America 147
AF - Africa 56
OC - Oceania 6
Totale 7.640
Nazione #
US - Stati Uniti d'America 2.300
GB - Regno Unito 1.492
CN - Cina 632
SG - Singapore 477
IT - Italia 332
DE - Germania 290
SE - Svezia 207
RU - Federazione Russa 173
FR - Francia 165
HK - Hong Kong 152
UA - Ucraina 121
BD - Bangladesh 114
IN - India 88
BR - Brasile 87
VN - Vietnam 72
NL - Olanda 68
KR - Corea 66
FI - Finlandia 55
EU - Europa 53
TR - Turchia 52
CI - Costa d'Avorio 44
IE - Irlanda 37
CA - Canada 36
JP - Giappone 33
CO - Colombia 30
ID - Indonesia 19
BE - Belgio 15
EC - Ecuador 11
GR - Grecia 10
DK - Danimarca 8
TW - Taiwan 6
AR - Argentina 5
AU - Australia 5
ES - Italia 5
MX - Messico 5
PL - Polonia 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
CL - Cile 4
IQ - Iraq 4
VE - Venezuela 4
CR - Costa Rica 3
CZ - Repubblica Ceca 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
PK - Pakistan 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CH - Svizzera 2
GT - Guatemala 2
LU - Lussemburgo 2
MA - Marocco 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
TT - Trinidad e Tobago 2
AL - Albania 1
AT - Austria 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GH - Ghana 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LC - Santa Lucia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
VI - Stati Uniti Isole Vergini 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.368
Città #
Southend 1.382
Ashburn 268
Singapore 256
Milan 150
Hong Kong 145
Santa Clara 131
Chandler 129
Beijing 128
San Jose 122
Seattle 111
Jacksonville 96
Dallas 86
Ann Arbor 70
Wilmington 70
Council Bluffs 68
Berlin 64
Princeton 61
Los Angeles 57
Woodbridge 56
Dearborn 55
Fairfield 54
Abidjan 44
Bengaluru 40
Mountain View 39
Nanjing 39
Dublin 37
Redmond 37
Jinan 35
Serra 33
Houston 31
Moscow 29
Bogotá 28
Helsinki 28
Boardman 27
New York 26
Andover 25
Ho Chi Minh City 25
Sakarya 25
Shanghai 25
Lauterbourg 24
Shenyang 24
Buffalo 23
Tianjin 22
Guangzhou 21
Phoenix 21
Frankfurt am Main 20
Hefei 20
Medford 20
Scranton 20
Cambridge 18
Seoul 18
Somerville 18
Toronto 18
Des Moines 17
Ningbo 17
Hangzhou 16
Brussels 15
Hanoi 15
The Dalles 15
Tokyo 15
Nanchang 14
Changsha 12
Columbus 12
Bühl 11
Jakarta 11
Kiez 11
Saint Petersburg 11
Athens 10
Hebei 10
Hillsboro 10
Chicago 9
Redwood City 9
Auburn Hills 8
Brooklyn 8
Cincinnati 8
San Diego 8
Shenzhen 8
São Paulo 8
Verona 8
Cangzhou 7
Falls Church 7
Lansing 7
Elk Grove Village 6
Fuzhou 6
Kunming 6
Nürnberg 6
Quanzhou 6
Turin 6
Bergamo 5
Da Nang 5
Denver 5
Eitensheim 5
Madison 5
Naples 5
Rome 5
Atlanta 4
Baghdad 4
Bitonto 4
Bloomsbury 4
Bologna 4
Totale 4.827
Nome #
Anti-EGFR Antibody Efficiently and Specifically Inhibits Human TSC2-/- Smooth Muscle Cell Proliferation. Possible Treatment Options for TSC and LAM 496
G protein-mediated signal transduction is affected in primary biliary cirrhosis 406
Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma : epidermal growth factor is the required growth factor 390
Expression of the anti-apoptotic protein survivin amd altered function of IGF-1 pathway in TSC2 brain tubers 317
Proliferation and invasiveness of human smooth muscle TSC2-/- : Effect of anti-EGFR and rapamycin 314
Characterization of LAM/TSC cells isolated from patient chylous 306
Survivin expression in tuberous sclerosis complex cells 304
Development of a LAM model by using human TSC2-/- cells derived from a renal angiomyolipoma : A pharmacological evaluation 297
TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival 297
A mouse LAM model by endonasal administration of human TSC2 deficient smooth muscle cells 291
Exploring the role of MKK7 in excitotoxicity and cerebral ischemia : a novel pharmacological strategy against brain injury 291
Pathogenesis and pharmacological evaluation of human TSC2 smooth muscle cells. Possible treatment options for TSC and lymphangioleiomyomatosis 285
Farmacologia 270
Human smooth muscle TSC2-/- cells cause lymphangiogenesis-like lung destruction in nude mice. Pharmacological repair 270
Un modello di linfangioleiomiomatosi con la somministrazione di cellule muscolari lisce umane TSC2-/- 266
Phenotype reversion of human TSC2-/- smooth muscle cells 259
PATHOGENESIS AND PHARMACOLOGY OF ISOLATED HUMAN TSC2 SMOOTH MUSCLE CELLS. NOVEL THERAPEUTIC PERSPECTIVES 257
Development of a LAM model by using human TSC2 deficient smooth muscle cells derived from a renal angiomylipoma 253
Role of HMG-CoA reductase inhibitors in controlling TSC2-/- ASM cell growth and proliferation 248
Molecular characterization of growth and survival of human TSC2 gene-deficient smooth muscle-like cells 242
An epigenetic event may underlies the TSC features in TSC2 ASM cells 239
Promoter methylation of TSC2 gene is important for pathogenesis of TSC and LAM lesions 239
Reversion of the phenotype of human TSC2-/- smooth muscle cells 237
Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM 236
Isolation and growth characterization of two types of human TSC2 gene-deficient cells 227
Pharmacological and biochemical characterization of isolated and in vitro grown human TSC2 gene-deficient smooth muscle-like cells 222
Pharmacological reversion of the phenotype of human TSC2-/- smooth muscle cells 181
Totale 7.640
Categoria #
all - tutte 17.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.236


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022342 0 0 0 19 30 13 43 11 75 44 16 91
2022/2023489 55 57 35 68 66 75 4 28 70 4 17 10
2023/2024319 12 19 18 26 80 42 3 29 12 14 26 38
2024/2025717 36 62 18 88 102 15 13 74 25 74 62 148
2025/20261.643 181 93 205 124 138 108 207 68 128 108 181 102
2026/2027341 86 91 100 64 0 0 0 0 0 0 0 0
Totale 7.640